Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company mainly engages in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology and other therapeutic fields. The Company's products are antibody-drug conjugates (ADCs) SKB264 and A166. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

Employees

1,837

Sector

Biotechnology & Medical Research

Calendar

09-01 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
15/07/25	349.20 $	+1.87%	420,114
14/07/25	342.80 $	+0.82%	594,557
11/07/25	340.00 $	+1.25%	333,214
10/07/25	335.80 $	-4.00%	371,200
09/07/25	349.80 $	+1.98%	373,200

Delayed Quote Hong Kong S.E., July 15, 2025 at 06:59 am

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

342.80HKD

Average target price

330.26HKD

Spread / Average Target

-3.66%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Hong Kong S.E. Other stock markets 06:59:45 15/07/2025 +03			5-day change	1st Jan Change
349.20 ^HKD	+1.87%		+1.81%	+113.84%

06-12	SKB Biopharma Raises HK$1.94 Billion from Share Placement	MT
06-12	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives A Clinical Trial Notice Approving the Investigational New Drug Application for the Its CLDN18.2-Directed Antibody-Drug Conjugate SKB315 in Combination of the Anti-Programmed Death Ligand 1 (PD-L1) Monoclonal Antibody Tagitanlimab	CI

Capitalization	71.54B 78.34B 9.98B 8.54B 7.95B 7.42B 13.66B 858B 15.22B 95.85B 36.34B 402B 37.43B 36.66B 1,472B	P/E ratio 2025 *	-115x	P/E ratio 2026 *	-834x
Enterprise value	70.15B 76.82B 9.79B 8.38B 7.8B 7.28B 13.39B 842B 14.92B 93.99B 35.63B 394B 36.7B 35.95B 1,444B	EV / Sales 2025 *	35.5x	EV / Sales 2026 *	22.9x
Free-Float	59.59%	Yield 2025 *	-	Yield 2026 *	-

SKB Biopharma Raises HK$1.94 Billion from Share Placement	06-12	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives A Clinical Trial Notice Approving the Investigational New Drug Application for the Its CLDN18.2-Directed Antibody-Drug Conjugate SKB315 in Combination of the Anti-Programmed Death Ligand 1 (PD-L1) Monoclonal Antibody Tagitanlimab	06-12	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination with Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer	06-11	CI
Sichuan Kelun-Biotech Lung Cancer Combo Gets Breakthrough Tag in China; Shares Slide 3%	06-11	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results from Phase 1/2 Study of Kelun-Biotech's Trop2 Adc Sacituzumab Tirumotecan	06-10	CI
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC	06-07	CI
SKB Biopharmaceutical Seeks to Raise HK$1.94 Billion from Share Placement; Shares Fall 7%	06-05	MT
Sichuan Kelun-Biotech Biopharmaceutical Placing 5.9 Mln Placing H Shares At HK$331.8 Per Placing H Share	06-05	RE
Accelerated Bookbuild Offering Of H Shares In Sichuan Kelun-Biotech Biopharmaceutical, Term Sheet Shows	06-04	RE
Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. to Present Results from Six Clinical Studies	05-23	CI
SKB Biopharmaceutical Gets Upfront Payment Under Drug License Contract	05-23	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives an Upfront Payment from Windward Bio AG	05-23	CI
Chinese Regulator Accepts SKB Biopharma's New Indication Application for Breast Cancer Drug	05-22	MT

Jefferies Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$300 from HK$240, Keeps at Buy	03-26	MT
Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy	02-18	MT
Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$195.51 From HK$196.40, Keeps at Buy	20/08/24	MT

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Stock

Equities

6990

CNE1000062J1

Biotechnology & Medical Research

Valuation: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Chart: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Latest news: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Analysts' recommendations: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Press Releases: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024	03-26	PR
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).	01-11	PR

1 day	+1.87%
1 week	+1.81%
Current month	+6.72%
1 month	-2.08%
3 months	+12.57%
6 months	+115.82%
Current year	+113.84%

1 week	329.8	354.4
1 month	314.2	370
Current year	153.9	380
1 year	142	380
3 years	60.6	380
5 years	60.6	380
10 years	60.6	380

Manager	Title	Age	Since
Jun You Ge CEO	Chief Executive Officer	53	01/03/2022
Ze Jian Zhou DFI	Director of Finance/CFO	42	17/08/2022
Xiao Ping Jin CTO	Chief Tech/Sci/R&D Officer	48	06/09/2021

Director	Title	Age	Since
Ge Xin Liu CHM	Chairman	74	01/03/2022
Jin Ping Jin BRD	Director/Board Member	53	15/02/2023
Yue Dong Li BRD	Director/Board Member	48	15/02/2023

	2025 *	2026 *
Net sales	1.97B 2.16B 275M 236M 219M 205M 377M 23.68B 420M 2.64B 1B 11.08B 1.03B 1.01B 40.62B	3.06B 3.35B 427M 365M 340M 317M 584M 36.71B 651M 4.1B 1.55B 17.17B 1.6B 1.57B 62.97B
Net income	-612M -670M -85.4M -73.1M -68.06M -63.51M -117M -7.34B -130M -820M -311M -3.44B -320M -314M -12.6B	-76.5M -83.78M -10.67M -9.13M -8.5M -7.94M -14.6M -918M -16.27M -102M -38.86M -429M -40.02M -39.2M -1.57B
Net Debt	-1.39B -1.52B -194M -166M -155M -144M -266M -16.7B -296M -1.86B -707M -7.81B -728M -713M -28.64B	-1.5B -1.64B -209M -179M -166M -155M -286M -17.94B -318M -2B -760M -8.39B -783M -766M -30.78B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.87%	+1.81%	+132.80%	-	9.98B
ARGENX SE	+1.44%	+4.61%	+13.01%	+34.09%	34.85B
WUXI APPTEC CO., LTD.	+1.88%	+12.54%	+102.58%	-27.05%	31.35B
BIONTECH SE	-1.67%	+0.86%	+30.67%	-28.14%	27.33B
INSMED INCORPORATED	+3.78%	+5.10%	+32.82%	+339.18%	19.35B
SUMMIT THERAPEUTICS INC.	+1.60%	+12.34%	+197.08%	+2,491.84%	18.86B
WUXI BIOLOGICS (CAYMAN) INC.	-0.56%	+3.50%	+140.07%	-65.00%	13.87B
GENMAB A/S	-0.44%	+4.89%	-25.66%	-45.10%	13.21B
AKESO, INC.	-0.25%	+7.38%	+205.84%	+418.24%	13.52B
EXELIXIS, INC.	+1.60%	+3.22%	+103.48%	+113.49%	12.43B
Average	+1.09%	+5.26%	+93.27%	+359.06%	19.48B
Weighted average by Cap.	+1.19%	+5.81%	+81.42%	+317.73%